ReviewCancers2019
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 137 citations in OpenAlex.
- Contrast-enhanced ultrasound and clinical features for preoperative prediction of GPC-3 expression in hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Development of Glypican 3-Targeting Antibody-Drug Conjugates for Hepatocellular Carcinoma Therapy.Cancer research communications · 2026Article
- Patient-Derived Organoid Modeling of Glypican-3 CAR-T Responses in Hepatocellular Carcinoma.Cells · 2026Article
- Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.JHEP reports : innovation in hepatology · 2026Article
- Serum Outperforms Plasma for Glypican-3 Quantification in Hepatocellular Carcinoma-A Prospective Comparative Study.Journal of clinical medicine · 2026Article
- An integrative omics-guided druggability analysis of VCX2 in hepatocellular carcinoma using Peruvian natural products.Frontiers in bioinformatics · 2026Article
- A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncology research · 2026Review
- Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma.Current issues in molecular biology · 2025Review
- Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.Cancers · 2025Review
- The Inhibitory Effects of Anti-GPC3 Antibody on Wnt/β-Catenin Signaling Pathway as a Biological Therapy in Liver Cancer.Molecular biotechnology · 2025Article
- Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.Journal of clinical and translational hepatology · 2025Review
- CAR-T cell therapy in china: innovations, challenges, and strategic pathways.Discover oncology · 2025Review
- Correlation between prognostic markers and clinical parameters in hepatocellular carcinoma: Pathophysiological aspects to therapeutic targets.World journal of gastrointestinal oncology · 2025Article
- Role of cancer cell-derived exosomal glycoproteins in macrophage polarization.Molecular biology reports · 2025Review
- Therapeutic Glypican-3 CRISPR Genome-Editing Using UltraLarge Porous Silica Nano-Depot for the Treatment of Hepatocellular Carcinoma.Small science · 2025Article
- The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.MedComm · 2025Review
- Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen.Advanced functional materials · 2025Article
- Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer.Lipids in health and disease · 2025Review
- Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression.Journal of translational medicine · 2025Article
- Current status and new directions for hepatocellular carcinoma diagnosis.Liver research (Beijing, China) · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glypican-3 (GPC3) is an oncofetal glycoprotein attached to the cell membrane by a glycophosphatidylinositol anchor. GPC3 is overexpressed in some kinds of tumors, particularly hepatocellular carcinoma (HCC). The prognostic significance of serum GPC3 levels and GPC3 immunoreactivity in tumor cells has been defined in patients with HCC. In addition to its usefulness as a biomarker, GPC3 has attracted attention as a novel therapeutic target molecule, and clinical trials targeting GPC3 are in progress. The major mechanism of anti-GPC3 antibody (GPC3Ab) against cancer cells is antibody-dependent cellular cytotoxicity and/or complement-dependent cytotoxicity. Since GPC3Ab is associated with immune responses, a combination of protocols with immune checkpoint inhibitors has also been investigated. Moreover, some innovative approaches for GPC3-targeting therapy have emerged in recent years. This review introduces the results of recent clinical trials targeting GPC3 in HCC and summarizes the latest knowledge regarding the role of GPC3 in HCC progression and clinical application targeting GPC3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.